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Summary Current global control efforts targeting tuberculosis (TB) include the
treatment of latent TB infection, case detection and treatment with directly
observed therapy short-course (DOTS), and BCG (bacille Calmette—Gue´rin) vaccina-
tion. However, BCG has been found to decrease only childhood TB morbidity and
mortality but has a very limited effect in the transmission dynamics of the infection.
These limitations of BCG are the driving force for the development of new TB
vaccines. New TB vaccine candidates have entered clinical evaluation and many
more are in the pipeline to undergo clinical testing. New vaccine candidates may offer
better protection than that afforded by currently available BCG vaccines. Further-
more, combined vaccination schedules against TB seem to be a promising strategy in
the new millennium.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Infectious diseases remain a major cause of death
worldwide and also represent an incalculable
source of human misery. More than 95% of these
deaths occur in the developing world.1,2 The three* Corresponding author. Tel.: +1 404 616 3600;
fax: +1 404 880 9305.
E-mail addresses: cfranco@sph.emory.edu,
carlos_franco@emoryhealthcare.org (C. Franco-Paredes).
1201-9712/$32.00 # 2005 International Society for Infectious Diseas
doi:10.1016/j.ijid.2005.06.002major infectious disease killers are HIV/AIDS,
tuberculosis (TB), and malaria. In 1993 the World
Health Organization (WHO) declared TB a global
emergency due to its medical, social, and economic
consequences.3
Currently, global control efforts targeting TB
include the treatment of latent TB infection
(LTBI), case detection and treatment with directly
observed therapy, and BCG vaccination.3 However,
altogether these strategies have had a limited
impact in reducing the global burden of TB despitees. Published by Elsevier Ltd. All rights reserved.
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on the use of directly observed therapy short-
course (DOTS) in many countries and the wide-
spread use of BCG vaccination in many regions of
the world.4 Although modern chemotherapy to
treat TB disease is highly effective, the effect
that the concomitant HIV pandemic has had on
TB, the length of treatment and the requirement
for multiple drug combinations have limited the
impact that thus far these global efforts to control
TB have had.5
The immunological events elicited by Mycobac-
terium tuberculosis infection are critical to the
clinical expression of the disease and to evaluate
vaccine efficacy.6 Data from clinical trials and obser-
vational studies have shown widely disparate results
with BCG vaccination.7 In some studies BCG use has
shown significant protection and in others offered
no benefit.8—24 Another downside to BCG vaccina-
tion has been concern regarding its safety.25—27 As a
result, there is an urgent global public health need
to develop newer efficacious and safer TB vaccines
that may have an impact in both preventing TB
infection and, in previously infected populations,
halting the progression to TB disease.28—32
The future role of current BCG vaccination
policies is unclear in the setting of the possible
introduction of newer TB vaccines. Therefore, the
objective of this study is to review the published
medical literature on the topic and objectively
analyze the possible impact of new TB vaccine
candidates and compare this information to the
known biomedical and public health impact of cur-
rently used BCG vaccines.The rise and fall of BCG
The BCG vaccine was prepared at the Institut Pas-
teur in Lille, France in 1921 by Calmette and Gue´rin
and consists of a live-attenuated strain of Mycobac-
terium bovis, a closely related subspecies of M.
tuberculosis. While working with culture medium
to decrease bacterial clumping ofM. bovis Calmette
and Gue´rin found that when beef bile was added the
virulence of the M. bovis strain was reduced. It was
after 231 serial passages between 1908 and1924,
that the vaccine offered protection in animal mod-
els.7,33—37 Recent genotypic analyses suggest that
the RD1 region of the M. tuberculosis genome,
which codes for nine proteins, is missing in BCG.33
Deletion of this region has been considered to be a
key event leading to the attenuation features of the
mycobacterial strain.38 The original BCG strain was
maintained by serial passage at the Institut Pasteur.
Before this original strain was lost, it was distributedto dozens of laboratories in many countries. Each
laboratory produced its own BCG and has main-
tained it by serial passages.3,4,34
Clinical use of BCG vaccines started during the
1920s.30 Its use was supported by the results of
early trials conducted by Heimbeck among nursing
students in Norway which demonstrated that nur-
sing students vaccinated with BCG had lower rates
of active TB when compared to those who did not
received the vaccine.39 Additional evidence came
from the first formal trials organized among North
American Indians in the 1930s.17—19,21 From 1929 to
1930, many orally vaccinated children in Lubeck,
Germany died of TB because the oral BCG prepara-
tion was contaminated with a virulent tubercle
strain.40 By the 1940s several other clinical studies
had confirmed the evidence of protection of BCG
vaccines.17—20 Subsequently, and based on the
recognition that tuberculosis rates increased in
the aftermath of World War II, vaccination was
widely applied by various international health
organizations.3,7,30 In the 1960s WHO developed
recommendations for routine BCG vaccination.30
BCG was incorporated into the Expanded Program
on Immunizations (EPI) infant vaccination schedule
in 1974.3,30 Today BCG vaccines are among the most
widely used in the world and have been adminis-
tered to over 3 billion individuals in over 80
years.3,30 Currently available BCG vaccines are
produced by more than 40 manufacturers around
the world.
While BCG is considered one of the oldest vac-
cines currently used throughout the world, policies
for its use differ between countries, and there is a
long-standing history of controversy concerning the
efficacy of BCG and its overall impact on TB.3—5,30
BCG vaccination policies can be divided into four
different categories: (1) those that recommend BCG
at birth or first contact with the healthcare system;
(2) those that recommend BCG only once in child-
hood; (3) those that recommend repeated BCG
boosters; and (4) those countries where BCG is
not recommended.3,30 Almost all countries of the
world, with the exception of a few industrialized
countries such as the United States and the Nether-
lands have routinely recommended BCG vaccina-
tion. The reasons for these variations in BCG
vaccination policies reflect medical and public
health strategies of the countries involved. Cur-
rently, the prevailing policy is only one dose at birth
as recommended by the WHO.3,4,30 The Interna-
tional Union against Tuberculosis and Lung Disease
(IUATLD) has developed criteria for a country to shift
from routine BCG vaccination to selective vaccina-
tion of only high risk groups, an approach recently
adopted in the United Kingdom.3,30
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When evaluating BCG vaccine efficacy it is funda-
mental to consider the protective effect of BCG
separately in children and adults. Different clinical
trials evaluating the efficacy of BCG have demon-
strated contradictory findings, varying from a BCG
efficacy rate in preventing adult pulmonary TB that
ranges from 0% in South India to 80% in the UK.7—24
Vaccination of children with BCG after birth, as
recommended by WHO, has not been shown to
prevent the majority of infectious pulmonary TB
cases among adults. In addition, it has never been
clearly established that using BCG boosters may
enhance or maintain protection against TB. When
the results from well-designed clinical controlled
trials are combined, with both children and older
individuals included, an efficacy of approximately
50% has been identified.15 The most recent meta-
analysis of previously published data reviewed 1264
titles or abstracts and 70 selected studies, but only
26 studies met the inclusion criteria. This analysis
revealed similar results to those above, with BCG
vaccination reducing the risk of developing TB by an
average of 50%.11
As controversial as has been the protective effect
of BCG on adult cases of pulmonary TB disease,
there is clear evidence that BCG provides consistent
and appreciable protection against tuberculous
meningitis and disseminated disease in children.8,9
A meta-analysis of five randomized controlled trials
andeight case-control studies demonstrated an aver-
age protection of 86% (95% CI 65—95%) for controlled
trials and 75%, (95% CI 61—84%) for case-control
studies.9 However, the evidence in terms of protec-
tion against pulmonary TB disease during childhood is
also controversial.8,9,30 When analyzing trials that
included mycobacterial naı¨ve cohorts of newborns
and infants with follow-up periods between 7 and 19
years, an efficacy rate of 73% is found.18—20,41
Various hypotheses have emerged to explain
the different results of various clinical trials with
BCG.3,7,22,23,30,41,42 One hypothesis attributes
the differences to the variation among strains of
BCG and another to previous exposure to various
environmental mycobacteria.23,38,43—45 The Chin-
gleput trial in South India, conducted in 1968,
evaluated two BCG strains, Paris/Pasteur versus
Danish/Copenhagen in an area with high tube-
rculin positive prevalence attributed to environ-
mental mycobacteria.3,22 This area also had high
rates of TB. The results of this trial showed that
neither vaccine was protective for pulmonary TB.
These results led to a series of other clinical
studies aimed at evaluating BCG use in different
populations.Several authors have evaluated whether the dif-
ferences in various biological properties of BCG
vaccines could explain the different observed
degrees of protection.23,33,43 Exposure to environ-
mental mycobacteria may explain some of the
observed variation in vaccine efficacy, perhaps by
a crossed-antigenicity effect evoking a hampered
BCG response when individuals have been previ-
ously exposed to environmental mycobacteria.23
A relevant aspect of TB pathogenesis that may
additionally impact BCG immunization efficacy is
exogenous reinfection. The mechanism of action of
the vaccine to induce protection is based on its
ability to limit bacillemia associated with primary
pulmonary infection.6 This hematogenous spread is
believed to be a central component of the patho-
genesis of TB.6,7,30,34,37 The contribution of exo-
genous reinfection in decreasing immunization
efficacy has been demonstrated, although the
extent of this contribution is not known.46,47 These
events are particularly relevant since exogenous
reinfection to the lung apex as a second pathway
to cavitary disease may be indistinguishable from
primary hematogenous seeding. Thus, these rein-
fection events may impact vaccine efficacy by
bypassing hematogenous dissemination blocked
by immunization, leading to continuing TB trans-
mission dynamics.
Finally, immunogenetic factors at a population
genetic level have been suggested as further
possible factors in BCG biological behavior, asso-
ciated with cellular immune mechanisms such as
specific HLA-haplotypes, interferon-g (INF-g) poly-
morphisms and to the NRAMP gene influencing
susceptibility to TB and other mycobacterial
infections.3,5,30,41,47Cross-protection of BCG against other
mycobacterial infections
The efficacy of BCG against leprosy and other myco-
bacterial infections is considered another important
benefit of using this vaccine. More than four clinical
trials and more than 10 observational studies have
all shown protection ranging from 20 to 80%.48—53
There is more evidence of protection against lepro-
matous leprosy than against tuberculoid leprosy and
therefore its use has significant public health impli-
cations, given the fact that the polar lepromatous
forms are considered to be responsible for most
transmission of leprosy in developing countries.
While there is no convincing evidence that the
use of booster doses of BCG provides additional
TB protection, there is enough evidence to support
the use of BCG boosters to protect against leprosy.50
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protection against lymphadenitis caused by non-
tuberculous mycobacteria and against Buruli ulcer
caused by Mycobacterium ulcerans.54 This evi-
dence is based upon observations where increases
in non-tuberculous mycobacterial lymphadenitis
were identified in child cohorts after universal
BCG vaccination policies were discontinued in
some European countries.43—45,55Adverse events of BCG vaccination
Overall, the side-effects associated with BCG are
tolerable and historically these adverse events have
varied with the use of different BCG strains.3,30,56,57
Nowadays, BCG is the only commonly used vac-
cine that induces ulceration at the inoculation site.
The probability of leaving a scar is lower when the
vaccine is administered during early infancy.3,30
Inoculation of BCG results in a local inflammatory
response that usually persists for several months.
The expected reaction is the formation of a cold
abscess at the site of injection that turns into a
papule after 2—3 weeks.3,41 The lesion reaches
maximum size at about 6 weeks, when the overlying
skin becomes thin and shiny and frequently ulce-
rates. This lesion usually heals at around 10 weeks.
Side effects are common, including local reactions
such as erythema, pain, and swelling in the admin-
istration site.3,30,41 Local abscesses have been
reported in 2% of vaccinees secondary to inadequate
administration technique when the vaccine is inocu-
lated into the subcutaneous space instead of being
intradermal. In addition, lymphadenitis occurs in
approximately 1% and osteitis in 0.04% of vaccine
recipients and has been reported mostly in Scandi-
navia and Eastern Europe.25—27,41 Other reports
have suggested that osteitis occurs at a rate of
3—7 per 100 000 vaccinations with predilection for
the metaphyses of the long bones, lower extremi-
ties, and ribs. However, serious adverse reactions
are rare, with an incidence of <1 case in 1 mil-
lion.3,24—26 Disseminated BCG infection occurs
mostly in immunocompromised infants with such
conditions as severe combined immunodeficiency,
and among children with HIV infection.24,25To BCG or not to BCG?
While it has become clear that the use of BCG
vaccines in millions of people in many areas of
the world has not impacted the epidemiology of
TB on a global scale, it is widely accepted that
millions of cases of meningeal and disseminatedtuberculosis in children have been prevented by
its widespread use in regions with high incidence
rates of TB. The reasons why BCG has failed to
reduce the global burden of TB are probably multi-
factorial. In addition, the impact of BCG vaccines is
difficult to demonstrate since the impact of this
vaccine is not as readily apparent as with other
routinely administered childhood vaccinations.
Furthermore, the main burden of TB is carried by
adults with pulmonary disease, in whom BCG has
consistently been shown to have no significant pro-
tective effect.58 However, recent long-term efficacy
data of BCG use has been reported after a follow-up
period of more than 60 years with surviving mem-
bers of a cohort of patients that participated in a
clinical trial between 1935 and 1938 among Amer-
ican Indians and Alaskan natives.10,29,59 In this
report BCG vaccination demonstrated an efficacy
of 52%, with incidence rates of 66 and 138 per
100 000 per year in the vaccinated and unvaccinated
groups, respectively. In this trial, BCG vaccine effi-
cacy persisted for more than 50 years, suggesting
that a single dose of an effective BCG vaccine may
have long-lasting protection.29,59 The results of this
trial have brought back to the surface the contro-
versy of longstanding protection of BCG vaccination
occurring during childhood and persisting during
adult life with a single dose of BCG.
Many regions of the world continue to have ele-
vated rates of TB disease that preclude the use of
preventive chemotherapy as the sole component of
TB prevention. It is in these regions that BCG vacci-
nation continues to be an important component of
the control strategies to decrease the complications
of TB disease. In this regard, our experience in
Mexico during the period 1986 to 2000 at the
National Immunization Council is illustrative. In
1992, the WHO Global Health Report noted that
Mexico had 37 626 cases of active TB. Despite this
number of TB cases, we have been able to demon-
strate the benefits of BCG vaccination as part of the
Expanded Program on Immunizations. In Mexico,
most children receive a BCG dose after birth or at
their first encounter with the health system. During
this period we identified a decreased rate of TB
meningitis in children that coincides with the
amount of routinely administered BCG doses
(Figure 1). Over the years, we have witnessed a
reduction in the rates as well in the absolute number
of TB meningitis cases in children with minimal
adverse events registered at the national vaccine
adverse events system.
A delay in vaccination after birth may fail to
prevent cases of childhood tuberculosis if a family
member who has the disease is present within the
household. Most transmission to children occurs
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Figure 1 Rates of tuberculous meningitis with regards to
the number of BCG vaccines administered in Mexico during
the period 1986—2000. *During the period 1989—1991,
there was a significant increase in the rates of TB menin-
gitis due to a decrease in vaccination coverage. Similar
trends were observed between 1993 and 1994, and
1996 and 1997. Source: National Immunization Council,
Mexico.before the adult source case is identified, and
given the short incubation period for meningeal
and disseminated TB, implies that the time to
medically intervene is very limited.58 Only effec-
tive BCG vaccination of children reduces the devel-
opment of meningeal disease. Therefore, regardless
of the absence of an effective reduction in the
transmission rates of TB, from a public health
perspective the benefits of BCG vaccination of
children in areas with high rates of TB clearly out-
weigh the risks.New TB vaccine candidates
Advances in tuberculosis research over the last few
years have been driven by genomics, proteomics,
and advances in immunology.60,61 With the sequen-
cing of the genome of M. tuberculosis much insight
has been gained into the pathogenesis of the
infection and lines of molecular research to pro-
mote the development of new TB vaccines have
been established.62 These approaches have refined
the selection of potential candidate antigens of
M. tuberculosis. With one third of the human
population worldwide infected with M. tuberculo-
sis a post-exposure or post-infection vaccine
should be considered a major target in the TB
vaccine development efforts.14,61,62 Overall, it
has been estimated that even a highly effective
vaccine (50 to 90%) will only reduce the number
of TB cases by one third. However, this partial
benefit may translate into reduced TB mortality
rates and decreased emergence of multidrug-resis-
tant strains.14The development of vaccines is focused on the
induction of protection by generating an immune
response similar to natural infection without causing
disease, so that re-infection does not occur.37,41 In
the case of TB, the associated high rates of reacti-
vation and re-infection discloses the inefficient
immunity evoked by natural infection. Newer
approaches are thus required, to rationally design
new TB vaccines in order to evoke a superior
immune response than that induced by natural TB
infection.5
The primary goal of TB vaccines is to induce
memory pools of Th1-type cells that are considered
the main effectors in acquiring immunity against M.
tuberculosis.5,13,62 Both CD4+ and CD8+ T-cells play
a major role in optimal protection against TB. His-
torically, the lack of reliable laboratory or serologic
markers for immunity to mycobacteria has nega-
tively impacted on efforts to determine how BCG
affects the host and what level of protection it
provides.5 While there is extensive evidence that
INF-g secreting T-cells are an essential component
of mycobacterial immunity, it remains to be deter-
mined whether the ability of a vaccine to prime such
cells is correlated with its protective efficacy.5,60,61
To answer this issue, novel whole blood intracellular
cytokine detection assays have been developed to
determine specific T-cell responses.63—66 These
assays have been shown to be specific and sensitive
for detecting mycobacteria-specific immunity fol-
lowing BCG vaccination performed in rural field
studies.63—65 A whole-blood luminescence model
assay has also been developed to detect changes
in the cellular immune responses to mycobacteria
induced by BCG vaccination. This optimized assay,
which measures immune responses to mycobacteria
by the use of reporter gene-tagged BCG (BCG lux),
has been determined to be a useful tool in evaluat-
ing the immunogenicity of newly developed vaccine
candidates prior to large field trials in developing
countries to assess vaccine efficacy.64
Vaccines under development are being designed
using either live attenuated mycobacteria, or by
attempting to deliver selected mycobacterial genes
or gene products. Biological strategies currently
under evaluation include: use of prime-boost
approaches, subunit vaccines, DNA vaccines, mod-
ifying currently available BCG vaccines, or attenu-
ating M. tuberculosis strains.41,60—62
Tuberculosis vaccine research has shifted from
developing new vaccine candidates, to selecting the
best vaccines for clinical evaluation.13 Approxi-
mately 268 TB vaccine candidates have been ana-
lyzed for their ability to protect against M.
tuberculosis infection in animal models. Many of
these successful candidates identified in experimen-
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trials in humans.5,41,62Prime-boost vaccines
The use of vaccination to induce a protective
humoral immune response is a widely established
principle to protect against many infectious patho-
gens.67 In general, repeated vaccination with the
same vaccine results in higher levels of antibodies.
The prime-boost approach is based on the concept
of successive administration of the same mycobac-
terial antigen. Homologous boosting refers to the
antigens being delivered by the same delivery sys-
tem with each subsequent dose.28,67,68 Heterolo-
gous boosting consists of the successive
administration of the same mycobacterial antigens
expressed by different vaccine vectors, such as
intramuscular administration of naked DNA expres-
sing the antigen followed by intradermal inoculation
with a modified Vaccinia virus expressing the same
mycobacterial antigen.67
Vaccination against intracellular pathogens
such as M. tuberculosis needs to induce strong
cellular immune responses.5 In this regard, hetero-
logous-boosting approaches using mycobacterial
antigen have been shown to improve the induction
of cell-mediated immunogenicity of vaccine
candidates.28,67 In the case of M. tuberculosis het-
erologous prime-boost immunization strategies
have been shown to induce higher levels of both
CD4+ and CD8+ T-lymphocytes than homologous
boosting. Recombinant pox-viruses have been used
efficiently to induce this particular type of
response. Using BCG as the priming immunization
by this prime-boost approach seems to be a prac-
tical solution that provides for the beneficial
effects of BCG in children to be maintained into
adulthood.67,68
The results of some of these phase 1 trials
with the MVA subunit vaccine have already been
published.68 The initial trial focused on using the
prominent mycobacterial antigen 85A delivered as
a recombinant smallpox vaccine (modified vaccinia
Ankara, MVA); the 85A antigen is conserved among
all mycobacterial species and is present in all
strains of BCG.28,68 It has been suggested that in
the case of TB, by incorporating BCG into such a
prime-boost schedule, the protective effects of
BCG might be retained.68 The trial was conducted
in Oxford, UK, where school children no longer
routinely receive BCG, and demonstrated a safety
profile and adequate immunogenicity. Interest-
ingly, individuals who had previously received
BCG and received the MVA85A vaccine as a boosterdeveloped stronger immune responses that at 24
weeks were 5 to 30 times higher than those in BCG-
naı¨ve volunteers.68Subunit vaccines
Subunit vaccines deliver specific mycobacterial
immunogenic antigens that have the ability to
induce a protective effect.41 These antigens are
delivered in one or more forms: protein or peptides
(sometimes given in a combination of various pro-
teins), DNA, or live vectors.41,60,62 The subunit
approach would require only one or more antigens
intended to induce specific subpopulations of CD4+
T-cells and perhaps of some CD8+ T-cells, whereas a
whole bacterial vaccine attempts to stimulate many
T-cell subpopulations at the same time.41
Modifying current BCG vaccines by restoring lost
genes or increasing the expression of remaining
antigen-producing genes might become an ideal
strategy. The most studied gene in the RD1 region
is responsible for encoding ESAT-6, a protein of
unknown function that stimulates a strong T-cell
response.5,62 The immune response to ESAT-6 has
been shown to be an element of protective immu-
nity, and subunit vaccines that induce ESAT-6 reac-
tive T-cells provide partial protection against
tuberculosis in animal models.5,41
Pym et al.38 have demonstrated that several
genes in the RD1 region are required for secretion
of ESAT-6, which was also shown to be an essential
component in the induction of an optimal T-cell
response. They also observed that immunization
with a recombinant BCG strain carrying the RD1
region improves protection against aerosol chal-
lenge with M. tuberculosis in animal models. An
interesting observation in this animal model was
that it decreased the amount of the bacterial load
identified in the spleen, which suggests an enhanced
ability to restrict the hematogenous spread of M.
tuberculosis.38,69 In addition, combination of immu-
nodominant secreted antigens such as ESAT-6 and
Ag85B have shown protection in animal models.41,69DNA vaccines
DNA that encodes mycobacterial antigens can be
inserted together with a suitable promoter in a
bacterial plasmid.70 The intramuscular injection
of this complex induces an immune response to
the mycobacterial antigen encoded by the DNA. In
this manner, the response is strong, since bacterial
DNA, unlike vertebrate DNA, is recognized as foreign
by vertebrates because of its high content of
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these motifs are recognized by toll-like receptors
that are expressed by different cells of the innate
immune system, and therefore stimulate the pro-
duction, activation, and maturation of dendritic
cells. These cells, in turn, preferentially induce a
Th1 CD4+ response.62 Some plasmids may be admi-
nistered adsorbed to tiny beads and blasted through
the skin and enter Langerhans’ cells directly, sub-
sequently activating the same Th1 cascade that
controls many intracellular bacterial infec-
tions.41,60,70 DNA vaccination strategies with plas-
mid encoding proteins Ag85 and Hsp65 are now in
the pipeline. Hsp65 is a highly conserved antigen
from Mycobacterium leprae that has shown protec-
tion equal to BCG in the mouse model.72,73 However,
studies in non-human primates and clinical phase 1
studies in humans, suggest that the strong cellular
immune responses seen in small animals are often
not found when these vaccines are tested in larger
species.41,71—77Attenuated vaccines
Attenuated BCG or M. tuberculosis whole cell vac-
cines have also been evaluated as possible vaccine
candidates.41,60—62 The goal of this approach is to
inactivate particular groups of genes associated to
virulence of these strains while maintaining the
ability to induce protective immune responses.
Some of the strategies to obtain these effects using
whole cell live vaccines include: modifying their
amino acid biosynthetic pathways (BCG or M. tuber-
culosis); nutritionally deficient strains (BCG or M.
tuberculosis); diminished superoxide dismutase
activity (BCG) or overexpression of Ag85 (BCG); or
BCG administered in combination with IL-12 to
enhance CD4+ Th1 T-cell immune responses.41
The worldwide epidemic of HIV/AIDS infection
has had a profound impact on the epidemiology of
TB and may have implications for the use of BCG.75
In the process of designing effective and safer TB
vaccine candidates it is fundamental to consider
the use of these possible vaccines in a setting
where HIV/AIDS infection is highly prevalent or
where co-infection between TB and HIV is fre-
quent.41,60,62 Whole-cell inactivated vaccines such
as those containing Mycobacterium vaccae have
shown protection against TB in animal models by
evoking potent mycobacteria-specific cytotoxic
responses.76—78 Human studies with this vaccine
preparation have demonstrated a safety profile, as
well as immunogenicity in both healthy and HIV-
infected individuals.41,76,77 However, a heat-killed
M. vaccae vaccine demonstrated no significantprotection to reduce TB in HIV-infected popula-
tions in Tanzania.76—79
Clinical trials will be initiated with two other
whole cell vaccine candidates: one using a BCG
strain that produces a similar antigen 85A, and
the second one that consists of two other antigenic
proteins delivered in an adjuvant formulation. A
clinical phase 1 trial is underway in approximately
50 adults in the Boland—Overberg region of South
Africa to evaluate the safety and immunogenicity
over a 5-year period of the rBCG30 vaccine adminis-
tered intradermally.13,41 This enhanced BCG vaccine
(rBCG30) was chosen for its ability to over-express
the antigen 85B, when a plasmid coding for the 30-
kDa protein is introduced.13,41 The antigen 85B is a
major secretory or extracellular protein and has
been shown to be highly immunogenic and able to
induce protective responses in mice and guinea
pigs.61,62,74
In summary, a tuberculosis vaccine that would
be able to induce protection in populations that
have not had natural exposure to M. tuberculosis
(pre-exposure) and in those that have already been
exposed or that have previously received BCG
vaccination (post-exposure) would be ideal.13,14,31
The working group on vaccine development of the
Stop TB initiative of the WHO has identified three
major challenges to promote synergy and to accel-
erate identification and introduction of the most
effective vaccination strategy. These challenges
include initiation of phase 1 trials, developing
an iterative structure for clinical trials, and the
logistic and financial challenges associated with
phase 3 trials.13Combined strategies to control TB in
the new millennium
In the case of TB, effective global control will
require the use of combined strategies. Strengthen-
ing early diagnosis of cases with institution of effec-
tive chemotherapy using DOTS is critical, however
there is still a clear need for TB vaccines. Pre-
exposure vaccines will be required to prevent infec-
tion and post-exposure vaccines, aimed to prevent
or reduce progression to disease, will also be of
benefit once a person is already infected. The pro-
tective effect of BCG demonstrated in childhood
tuberculosis might be enhanced by vaccination stra-
tegies that improve BCG rather than completely
replacing its use. Boosting vaccinations such as
demonstrated with MVA85A could offer an efficient
strategy for enhancing and prolonging anti-myco-
bacterial immunity in areas with elevated rates of
TB.80 It has been suggested in mathematical models
100 C. Franco-Paredes et al.that a vaccine that can induce protection by redu-
cing infection and preventing progression of disease
might be ideal.
It is anticipated that many more new TB vaccine
candidates will be developed and become available
to be tested in human populations in the coming
years. With the advent of improved TB vaccines,
current BCG vaccination policies will be modified.
However, until this moment arrives, and taking into
account current scientific evidence of the protec-
tive effects of BCG vaccination, we strongly believe
that in resource-limited countries, such as most
developing countries, with high rates of TB infection
and disease, there are compelling reasons to con-
tinue its routine use.
Finally, a major commitment from the developed
world is needed to drastically improve social and
economic conditions in resource-poor settings.
Many have argued that without changing these
structural factors, strategies such as widespread
implementation of DOTS and preventative measures
such as widespread vaccination with BCG, or the use
of newer TB vaccine candidates will not succeed as
expected in controlling the resurgent tuberculosis
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